Received Jun 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 57DD5 | — |
A 31 years old female patient received Priorix IM instead of subcutaneous.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a 31-year-old female patient who received MMR (Priorix) (batch number 57DD5, expiry date 01-DEC-2026) for prophylaxis. On an unknown date, the patient received Priorix. On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: A 31 years old female patient received Priorix IM instead of subcutaneous.). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 27-MAY-2025 The reporter reported on 27/MAY/2025 a pharmacist called to report that a 31 years old female patient received Priorix Intramuscular instead of subcutaneous, which led to subcutaneous injection formulation administered by other route.